Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
Fiche publication
Date publication
mars 2020
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM
Lien Pubmed
Résumé
Stage IV small cell lung cancer (SCLC) is associated with short survival and progression after first-line systemic therapy frequently occurs within months. Although topotecan is approved for second-line treatment, its efficacy is limited, and treatment heterogeneity exists.
Mots clés
Decision making, Objective consensus, Second-line chemotherapy, Small cell lung cancer (SCLC)
Référence
Lung Cancer. 2020 Mar 30;146:6-11